{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:24Z","timestamp":1791396084966,"version":"4.3.3"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thrombocythemia (ET), but their prevalence and significance remain unclear. The JAK2 mutation status of 6495 BFU-E, grown in low erythropoietin conditions, was determined in 77 patients with PV or ET. Homozygous-mutant colonies were common in patients with JAK2V617F-positive PV and were surprisingly prevalent in JAK2V617F-positive ET and JAK2 exon 12-mutated PV. Using microsatellite PCR to map loss-of-heterozygosity breakpoints within individual colonies, we demonstrate that recurrent acquisition of JAK2V617F homozygosity occurs frequently in both PV and ET. PV was distinguished from ET by expansion of a dominant homozygous subclone, the selective advantage of which is likely to reflect additional genetic or epigenetic lesions. Our results suggest a model in which development of a dominant JAK2V617F-homzygous subclone drives erythrocytosis in many PV patients, with alternative mechanisms operating in those with small or undetectable homozygous-mutant clones.<\/jats:p>","DOI":"10.1182\/blood-2012-05-431791","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T23:22:49Z","timestamp":1345159369000},"page":"2704-2707","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":98,"title":["JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone"],"prefix":"10.1182","volume":"120","author":[{"given":"Anna L.","family":"Godfrey","sequence":"first","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"},{"name":"Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Chen","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pagano","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Ortmann","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Silber","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[{"name":"University Hospital of Ulm, Department of Internal Medicine III, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fontanet","family":"Bijou","sequence":"additional","affiliation":[{"name":"Etablissement Fran\u00e7ais du Sang Aquitaine Limousin, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[{"name":"Laboratoire d'Hematologie, Centre Hospitalier Universitaire de Bordeaux and Laboratorie Hematopoiese Leucemique et Cibles Th\u00e9rapeutiques, Inserm U 1035, Universit\u00e9 Bordeaux Segalen, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"McMullin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Belfast City Hospital, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Boiron","sequence":"additional","affiliation":[{"name":"Department of Haematology, H\u00f4pital Haut-L\u00e9v\u00e8que, Etablissement Fran\u00e7ais du Sang Aquitaine-Limousin, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"University Hospital of Ulm, Department of Internal Medicine III, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Care, Section of Hematology, University of Florence and Istituto Toscano Tumori, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Besses","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital del Mar-IMIM, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Green","sequence":"additional","affiliation":[{"name":"Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"},{"name":"Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9464","key":"2019111809225840800_B1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"2019111809225840800_B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"7037","key":"2019111809225840800_B3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2019111809225840800_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111809225840800_B5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111809225840800_B6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111809225840800_B7","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111809225840800_B8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111809225840800_B9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111809225840800_B10","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111809225840800_B11","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2008-07-167056","article-title":"Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the pre-disposing mutations for JAK2-V617F.","volume":"113","author":"Schaub","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2019111809225840800_B12","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111809225840800_B13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111809225840800_B14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111809225840800_B15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"issue":"9","key":"2019111809225840800_B16","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"issue":"6","key":"2019111809225840800_B17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2141.2007.06741.x","article-title":"Amendment to the guideline for diagnosis and investigation of polycythaemia\/erythrocytosis.","volume":"138","author":"McMullin","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111809225840800_B18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis.","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111809225840800_B19","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111809225840800_B20","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019111809225840800_B21","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111809225840800_B22","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"2019111809225840800_B23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111809225840800_B24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2019111809225840800_B25","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.","volume":"359","author":"Zhao","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/13\/2704\/1358517\/zh803912002704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/13\/2704\/1358517\/zh803912002704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:25:10Z","timestamp":1574072710000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/13\/2704\/30825\/JAK2V617F-homozygosity-arises-commonly-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-431791","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}